Overview

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the 3 years DFS of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer. The other purpose of this trial is to observe the patient's tolerance.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cyclophosphamide
Epirubicin
Paclitaxel